Cargando…

Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

PURPOSE: To summarise post-licensure safety surveillance over more than 4 years of routine use of the human papillomavirus-16/18-AS04-adjuvanted vaccine (HPV-16/18 vaccine: Cervarix®, GlaxoSmithKline, Belgium). METHODS: We describe global post-licensure passive surveillance data based on routine pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angelo, Maria-Genalin, Zima, Julia, Tavares Da Silva, Fernanda, Baril, Laurence, Arellano, Felix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265196/ https://www.ncbi.nlm.nih.gov/pubmed/24644078 http://dx.doi.org/10.1002/pds.3593

Ejemplares similares

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
por: Angelo, Maria-Genalin, et al.
Publicado: (2014)

Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom
por: Willame, Corinne, et al.
Publicado: (2016)

Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data
por: Huygen, Frank, et al.
Publicado: (2015)

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial
por: Lehtinen, Matti, et al.
Publicado: (2016)

Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania()()
por: Brown, Joelle, et al.
Publicado: (2014)

Meta‐analysis of the risk of autoimmune thyroiditis, Guillain‐Barré syndrome, and inflammatory bowel disease following vaccination with AS04‐adjuvanted human papillomavirus 16/18 vaccine
por: Rosillon, Dominique, et al.
Publicado: (2020)

Reciprocity in Licensure Once More
Publicado: (1903)

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
por: Vokó, Zoltán, et al.
Publicado: (2012)

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
por: Germar, Maria Julieta, et al.
Publicado: (2017)

From discovery to licensure, the Adjuvant System story
por: Garçon, Nathalie, et al.
Publicado: (2016)

Six‐year multi‐centre, observational, post‐marketing surveillance of the safety of the HPV‐16/18 AS04‐adjuvanted vaccine in women aged 10–25 years in Korea
por: Kim, Chul‐Jung, et al.
Publicado: (2017)

Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years
por: Bi, Dan, et al.
Publicado: (2019)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women
por: Kim, Seung Cheol, et al.
Publicado: (2011)

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
por: Kim, Young-Jae, et al.
Publicado: (2010)

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial
por: Huang, Li-Min, et al.
Publicado: (2017)

Automobile Licensure
Publicado: (1915)

Reciprocity in Licensure
Publicado: (1905)

Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh
por: Khatun, Sabera, et al.
Publicado: (2012)

Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study
por: Namujju, Proscovia B, et al.
Publicado: (2014)

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial
por: Zhu, Feng-Cai, et al.
Publicado: (2011)

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2019)

Reciprocity in Medical Licensure
por: Vander Veer, Albert
Publicado: (1907)

Reciprocity in Medical Licensure
Publicado: (1897)

Reciprocity in Medical Licensure
Publicado: (1897)

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women
por: Sow, Papa Salif, et al.
Publicado: (2013)

Erratum to: Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2020)

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
por: Folschweiller, Nicolas, et al.
Publicado: (2019)

Rypins' Medical Licensure Examinations
Publicado: (1952)

State Licensure for the Practice of Medicine
Publicado: (1894)

Board of Medical Licensure and Discipline
Publicado: (2022)

Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16.
por: Arends, M. J., et al.
Publicado: (1995)

Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
por: Costa, Ana Paula Ferreira, et al.
Publicado: (2018)

Medical licensure examinations; topical summaries and questions
por: Rypins, Harold, 1892-1939
Publicado: (1957)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
por: Folschweiller, Nicolas, et al.
Publicado: (2020)

Challenges to Licensure of Enterovirus 71 Vaccines
por: Lee, Min-Shi, et al.
Publicado: (2012)

Vaccines for emerging pathogens: prospects for licensure
por: Williamson, E. D., et al.
Publicado: (2019)

How Shall Reciprocity in Licensure Be Established?
Publicado: (1900)

Physical Therapy Licensure Compact Update
por: Adrian, Leslie
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mv0b59e0rpv2dn073qu0r6us3m